- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06068465
A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis
A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of Pimavanserin in the Treatment of Psychosis in Parkinson's Disease
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Rui Liu
- Phone Number: 022-86343626
- Email: liurui2@tasly.com
Study Locations
-
-
Anhui
-
Hefei, Anhui, China, 230061
- Recruiting
- The First Affiliated Hospital of Anhui Medical University
-
Contact:
- Kai Wang
- Email: wangkai1964@126.com
-
-
Beijing
-
Beijing, Beijing, China, 100005
- Recruiting
- Beijing Hospital
-
Contact:
- Haibo Chen
- Email: chenhbneuro@263.net
-
Beijing, Beijing, China, 100191
- Recruiting
- Peking University Sixth Hospital
-
Contact:
- Xinyu Sun
- Email: sunxinyu@bjmu.edu.cn
-
Beijing, Beijing, China, 100053
- Recruiting
- Xuan Wu Hospital
-
Contact:
- Hong Sun
- Email: sallysunhong@163.com
-
-
Chongqing
-
Chongqing, Chongqing, China, 400016
- Recruiting
- The First Affiliated Hospital of Chongqing Medical University
-
Contact:
- Oumei Chen
- Email: chengoumei@cqmu.edu.cn
-
-
Fujian
-
Fuzhou, Fujian, China, 350005
- Recruiting
- The First Affiliated Hospital of Fujian Medical University
-
Contact:
- Ning Wang
- Email: 26354378@qq.com
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510000
- Recruiting
- Guangdong Provincial Peoples Hospital
-
Contact:
- Lijuan Wang
- Email: wljgd68@163.com
-
-
Guizhou
-
Guiyang, Guizhou, China, 550001
- Recruiting
- The Affiliated Hospital Of Guizhou Medical University
-
Contact:
- Lijun Cai
- Email: cailijunj@126.com
-
-
Hebei
-
Shijiazhuang, Hebei, China, 050005
- Recruiting
- The Second Hospital of Hebei Medical University
-
Contact:
- Yaling Liu
- Email: lyldoctor@163.com
-
-
Henan
-
Zhengzhou, Henan, China, 450052
- Recruiting
- The First Affiliated Hospital of Zhengzhou University
-
Contact:
- Yuming Xu
- Email: 13903711125@126.com
-
-
Hunan
-
Changsha, Hunan, China, 410013
- Recruiting
- The Third Xiangya Hospital of Central South University
-
Contact:
- Lifang Lei
- Email: 525837843@qq.com
-
-
Inner Mongolia Autonomous Region
-
Hohhot, Inner Mongolia Autonomous Region, China, 010000
- Recruiting
- Inner Mongolia Autonomous Region People's Hospital
-
Contact:
- Runxiu Zhu
- Email: zhurunxiu@163.com
-
-
Jiangsu
-
Huaian, Jiangsu, China, 223022
- Recruiting
- Huai'an Second People's Hospital
-
Contact:
- Liandong Zhao
- Email: zldong@163.com
-
Nanjing, Jiangsu, China, 210008
- Recruiting
- Nanjing Drum Tower Hospital
-
Contact:
- Yun Xu
- Email: xuyun20042001@aliyun.com
-
Nanjing, Jiangsu, China, 210009
- Recruiting
- Zhongda Hospital Southeast University
-
Contact:
- Baoyu Yuan
- Email: Yuanby1978@163.com
-
Suzhou, Jiangsu, China, 215004
- Recruiting
- The Second Affiliated Hospital of Soochow University
-
Contact:
- Chunfeng Liu
- Email: liucf20@163.com
-
Xuzhou, Jiangsu, China, 221004
- Recruiting
- The Affiliated Hospital Of Xuzhou Medical University
-
Contact:
- Guiyun Cui
- Email: cuiguiyun-js@163.com
-
-
Jiangxi
-
Nanchang, Jiangxi, China, 330008
- Recruiting
- The Second Affiliated Hospital of Nanchang University
-
Contact:
- Wei Huang
- Email: 13677080198@163.com
-
-
Jilin
-
Changchun, Jilin, China, 130021
- Recruiting
- The First Hospital of Jilin University
-
Contact:
- Yin Zhang
- Email: rose19700@sina.com
-
-
Liaoning
-
Shenyang, Liaoning, China, 110002
- Recruiting
- The First Hospital of China Medical University
-
Contact:
- Chuansheng Zhao
- Email: cszhao@cmu.edu.cn
-
-
Ningxia Hui Autonomous Region
-
Yinchuan, Ningxia Hui Autonomous Region, China, 750002
- Recruiting
- People's Hospital of Ningxia Hui Autonomous Region
-
Contact:
- Yuan Wu
- Email: jluwuyuan@163.com
-
-
Shandong
-
Jinan, Shandong, China, 250012
- Recruiting
- Qilu Hospital of Shandong University
-
Contact:
- Yiming Liu
- Email: Liuym@sdu.edu.cn
-
Qingdao, Shandong, China, 266035
- Recruiting
- Qilu Hospital of Shandong University(qingdao)
-
Contact:
- Cuiping Zhao
- Email: zhaocuipingzsu@126.com
-
-
Shanghai
-
Shanghai, Shanghai, China, 200025
- Recruiting
- Ruijin Hospital
-
Contact:
- Shengdi Chen
- Email: ruijincsd@126.com
-
-
Sichuan
-
Chengdu, Sichuan, China, 610041
- Recruiting
- West China Hospital of Sichuan University
-
Contact:
- Huifang Shang
- Email: hfshang2002@163.com
-
Mianyang, Sichuan, China, 621099
- Recruiting
- Mianyang Central Hospital
-
Contact:
- Yufeng Tang
- Email: dryufeng@126.com
-
-
Tianjin
-
Tianjin, Tianjin, China, 300222
- Recruiting
- Tianjin Huanhu Hospital
-
Contact:
- Lei Chen
- Email: halo1881@163.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female of 40 years of age or older;
- A clinical diagnosis of Parkinson's disease with a minimum duration of 1 year;
- Subjects must have had psychotic symptoms that developed after the diagnosis of Parkinson's disease was established. These symptoms must have included visual hallucinations and/or auditory hallucinations, and/or delusions;
- Psychotic symptoms were to have been present for at least one month and the subject must have been actively experienced psychotic symptoms each week during the month prior to the Screening visit;
- Symptoms severe enough to warrant treatment with an antipsychotic agent; documented at screening by items A and B of the NPI, and defined as a score of 4 or greater on either the Hallucinations (Frequency x Severity) or Delusions (Frequency x Severity) scales OR a total combined score of 6 or greater;
- At the baseline visit, subject must have had a SAPS Hallucinations or Delusions global item (H7 or D13) score ≥3 AND a score >3 on at least one other non-global item using the modified 9-item SAPS Hallucinations and Delusions domains;
- Subject must have had a clear sensorium at study entry (i.e., oriented to time, person, and place);
- Subject must have been on stable dose of anti-Parkinson's medication for 1 month prior to Day 1 (Baseline) and during the trial;
- If a Subject had received stereotaxic surgery for sub-thalamic nucleus deep brain stimulation they must have been at least 6 months post-surgery and the stimulator settings must have been stable for at least 1 month prior to Day 1 (Baseline) and must remain stable during the trial;
- Subjects of reproductive age (male/female) must have agreed to use a clinically acceptable method of contraception for at least one month prior to randomization, during the study, and one month following completion of the study;
- The subject was required to be willing and able to provide consent;
- Caregiver was required to be willing and able to provide consent and agrees to accompany the subject to all visits.
Exclusion Criteria:
- Subject with psychotic symptoms (hallucinations and delusions) which could be better explained as a part of a toxic, metabolic or infection-induced delirium /encephalopathy , psychosis due to substance abuse, psychosis associated with schizophrenia, bipolar disorder or psychotic depression;
- Subject who was likely to have an allergy or sensitivity to pimavanserin based on known allergies to drugs of the same class;
- Subject who had previously been randomized in any prior clinical study with pimavanserin, and/or received of any other investigational;
- Subject with a history of significant psychotic disorders prior to or concomitantly with the diagnosis of Parkinson's disease including, but not limited to, schizophrenia or bipolar disorder;
- Subjects had a significant risk of excitability or committing suicide based on the investigator's judgement; Any suicidal behavior in the year prior to or during screening; Subjects with a Columbia-Suicide Severity Rating Scale (C-SSRS) positive response to suicidal ideation items 4, or 5 are not eligible during the screening period.
- Subject with atypical Parkinsonism (Parkinson's plus, MSA, PSP), or secondary parkinsonism variants such as tardive or medication induced parkinsonism;
- Subject who had received previous ablative stereotaxic surgery (i.e., pallidotomy and thalamotomy) to treat Parkinson's disease;
- Had a score on the Mini-Mental State Examination (MMSE) of <21;
- Subject who had dementia prior to or concomitantly with the diagnosis of Parkinson's disease that may be inconsistent with a PD diagnosis;
- Subject who had history of cerebrovascular ischemic syndrome (stroke) that impairs their ability to complete the MMSE;
- Subject who was using any of the medications prohibited or restricted as described in(Prohibited and Restricted Concomitant Medications-below);
- Subject who was on medications of antidepressant/anxiety known to prolong the QT interval, the dose of medication cannot be maintained for 21 days before the baseline period;
- Subject who was on medications of acetylcholinesterase inhibitors,the dose of medication was not guaranteed to remain constant between the first 21 days of the baseline period and the last visit;
- Subject who had current evidence of a serious and or unstable cardiovascular, respiratory, gastrointestinal, renal, hematologic or other medical disorder, including cancer or malignancies,which would affect the subject's ability to participate in the study;
- Subject who had a myocardial infarction in last six months or who had moderate to severe congestive heart failure (NYHA class III or IV);
- Subject who had a screening and baseline electrocardiogram (ECG) with Bazett's corrected QT (QTcB) of greater than 460 msec if male or 470 msec if female or Subject who was known history or symptoms of long QT syndrome;
- Alanine aminotransferase (ALT) or glutamic aminotransferase (AST) or total bilirubin (TBiL) in laboratory tests were higher than 2 times the upper limit of normal during screening or baseline. Or severe impairment of renal function (defined as creatinine clearance Ccr < 30 ml/min. Creatinine clearance was calculated according to the Cockcroft-Gault formula); or other abnormal indicators in laboratory tests have clinical significance and are judged by the investigators to have safety risks;
- Subject who was pregnant or breastfeeding.,female subjects of childbearing potential who have positive pregnancy test results;
- Subject who had any surgery planned during the screening, treatment or follow-up periods;
- Subject who had participated in any clinical trial and used investigational drug within 4 weeks prior to enrollment;
- The investigator considered that the subjects had poor compliance or other factors that made it inappropriate to participate in the clinical trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Pimavanserin tartrate
Pimavanserin, 34 mg, capsule,once daily by mouth for 6 weeks Interventions
|
pimavanserin tartrate, 34 mg, capsule, once daily by mouth for 6 weeks
|
Placebo Comparator: Placebo
Placebo, capsule, once daily by mouth for 6 weeks
|
placebo, capsule, once daily by mouth for 6 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Antipsychotic Efficacy
Time Frame: Study Days 1 and 43
|
Antipsychotic Efficacy was defined as a decrease in the severity and/or frequency of hallucinations and/or delusions. This is measured as the change from baseline (Day 1) to Day 43 in the Scale for the Assessment of Positive Symptoms 9-item sum score for Parkinson's Disease (SAPS-PD). The possible total score is 0 to 45 and a negative change in score indicates improvement. Analysis Method: Analysis of Covariance,ANCOVA |
Study Days 1 and 43
|
Collaborators and Investigators
Investigators
- Study Director: Rui Liu, Tianjin Tasly Sants Pharmaceutical Co., Ltd
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Schizophrenia Spectrum and Other Psychotic Disorders
- Parkinsonian Disorders
- Basal Ganglia Diseases
- Movement Disorders
- Synucleinopathies
- Neurodegenerative Diseases
- Psychotic Disorders
- Parkinson Disease
- Mental Disorders
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Antipsychotic Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Serotonin Agents
- Serotonin 5-HT2 Receptor Antagonists
- Serotonin Antagonists
- Antiparkinson Agents
- Anti-Dyskinesia Agents
- Pimavanserin
Other Study ID Numbers
- TSL-CM-JSSPMFSL-Ⅲ
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson's Disease Psychosis
-
VA Office of Research and DevelopmentRecruitingParkinson's Disease PsychosisUnited States
-
ACADIA Pharmaceuticals Inc.CompletedParkinson's Disease PsychosisFrance, United States, Bulgaria, Russian Federation, United Kingdom, Ukraine, India
-
ACADIA Pharmaceuticals Inc.CompletedParkinson's Disease PsychosisUnited States, Austria, France, Canada, Belgium, Russian Federation, Serbia, Ukraine, Poland, Portugal, Italy, India, United Kingdom, Sweden
-
ACADIA Pharmaceuticals Inc.CompletedParkinson's Disease PsychosisSpain, United States, Belgium, Austria, Serbia, Poland, Portugal, Italy, Sweden
-
ACADIA Pharmaceuticals Inc.Approved for marketingParkinson's Disease Psychosis
-
ACADIA Pharmaceuticals Inc.CompletedParkinson's Disease PsychosisUnited States, Canada
-
The University of Texas Health Science Center at...Alzheimer's AssociationRecruitingDementia With Lewy Bodies | Parkinson's Disease PsychosisUnited States
-
ACADIA Pharmaceuticals Inc.CompletedParkinson's Disease PsychosisUnited States
-
SunovionCompletedParkinson Disease PsychosisUnited States
-
ACADIA Pharmaceuticals Inc.CompletedParkinson Disease PsychosisUnited States
Clinical Trials on pimavanserin tartrate
-
ACADIA Pharmaceuticals Inc.Approved for marketingParkinson's Disease Psychosis
-
ACADIA Pharmaceuticals Inc.CompletedParkinson's Disease PsychosisSpain, United States, Belgium, Austria, Serbia, Poland, Portugal, Italy, Sweden
-
ACADIA Pharmaceuticals Inc.CompletedParkinson's Disease PsychosisUnited States
-
ACADIA Pharmaceuticals Inc.CompletedParkinson's Disease PsychosisUnited States, Austria, France, Canada, Belgium, Russian Federation, Serbia, Ukraine, Poland, Portugal, Italy, India, United Kingdom, Sweden
-
ACADIA Pharmaceuticals Inc.CompletedParkinson's Disease PsychosisUnited States, Canada
-
ACADIA Pharmaceuticals Inc.CompletedAlzheimer's Disease PsychosisUnited Kingdom
-
ACADIA Pharmaceuticals Inc.CompletedParkinson's Disease PsychosisFrance, United States, Bulgaria, Russian Federation, United Kingdom, Ukraine, India
-
New York State Psychiatric InstituteWeill Medical College of Cornell University; University of Kansas Medical Center and other collaboratorsNot yet recruitingAutism Spectrum DisorderUnited States
-
ACADIA Pharmaceuticals Inc.CompletedDementia-related PsychosisUnited States, Spain, Poland, Ukraine, Chile, Czechia, United Kingdom, Bulgaria, France, Germany, Italy, Serbia, Slovakia
-
ACADIA Pharmaceuticals Inc.TerminatedAgitation and Aggression in Alzheimer's DiseaseUnited States, France, Spain, Chile, United Kingdom